Cargando…

Clustering on longitudinal quality‐of‐life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial

INTRODUCTION: Analyzing longitudinal cancer quality‐of‐life (QoL) measurements and their impact on clinical outcomes may improve our understanding of patient trajectories during systemic therapy. We applied an unsupervised growth mixture modeling (GMM) approach to identify unobserved subpopulations...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jiahui, Kong, Weili, Hu, Pingzhao, Jonker, Derek, Moore, Malcolm, Ringash, Jolie, Shapiro, Jeremy, Zalcberg, John, Simes, John, Tu, Dongsheng, O'Callaghan, Chris J., Liu, Geoffrey, Xu, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028035/ https://www.ncbi.nlm.nih.gov/pubmed/36281472 http://dx.doi.org/10.1002/cam4.5341

Ejemplares similares

Evaluating the Time Toxicity of Cancer Treatment in the CCTG CO.17 Trial
por: Gupta, Arjun, et al.
Publicado: (2023)

Fc‐gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer
por: Shepshelovich, Daniel, et al.
Publicado: (2018)

Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results
por: Kennecke, Hagen F., et al.
Publicado: (2023)

The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma
por: Renouf, Daniel J., et al.
Publicado: (2022)

The origin of genetic instability in CCTG repeats
por: Lam, Sik Lok, et al.
Publicado: (2011)

Germline Polymorphisms as Biomarkers of Tumor Response in Colorectal Cancer Patients Treated with Anti-EGFR Monoclonal Antibodies: A Systematic Review and Meta-Analysis
por: Morgen, Eric K, et al.
Publicado: (2017)

TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG)
por: Leong, Trevor, et al.
Publicado: (2015)

INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)
por: Lam, Lyn Ley, et al.
Publicado: (2023)

Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma
por: Mercieca-Bebber, R., et al.
Publicado: (2022)

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies
por: Hilton, John, et al.
Publicado: (2022)

Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer
por: Sjoquist, Katrin M., et al.
Publicado: (2022)

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial
por: Tebbutt, N C, et al.
Publicado: (2010)

The competing mini-dumbbell mechanism: new insights into CCTG repeat expansion
por: Guo, Pei, et al.
Publicado: (2016)

Contact Days Associated With Cancer Treatments in the CCTG LY.12 Trial
por: Gupta, Arjun, et al.
Publicado: (2023)

Myotonic Dystrophy-2: Unusual Phenotype Due to a Small CCTG-expansion
por: Finsterer, J, et al.
Publicado: (2018)

VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer
por: Chionh, Fiona, et al.
Publicado: (2022)

AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer
por: Oar, Andrew, et al.
Publicado: (2021)

Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG08.02) randomized clinical trial
por: Song, Andrew J, et al.
Publicado: (2021)

Corrigendum to: Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG 08.02) randomized clinical trial
por: Song, Andrew J, et al.
Publicado: (2022)

A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209
por: Eigl, Bernhard Josef, et al.
Publicado: (2018)

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer
por: Jonker, D J, et al.
Publicado: (2014)

Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial
por: Tebbutt, N C, et al.
Publicado: (2013)

Two-stage multivariate Mendelian randomization on multiple outcomes with mixed distributions
por: Deng, Yangqing, et al.
Publicado: (2023)

Early detection of treatment futility in patients with metastatic colorectal cancer
por: Rattner, Jodi I., et al.
Publicado: (2022)

Clinical and metabolomic characterization of Brivanib‐Induced hypertension in metastatic colorectal cancer
por: Rattner, Jodi I., et al.
Publicado: (2023)

Quality of Life, Toxicity and Unmet Needs in Nasopharyngeal Cancer Survivors
por: McDowell, Lachlan, et al.
Publicado: (2020)

Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer
por: Price, T J, et al.
Publicado: (2015)

SPAR – a randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: an AGITG clinical trial
por: Jameson, Michael B., et al.
Publicado: (2019)

The Unstable CCTG Repeat Responsible for Myotonic Dystrophy Type 2 Originates from an AluSx Element Insertion into an Early Primate Genome
por: Kurosaki, Tatsuaki, et al.
Publicado: (2012)

Development of South Australian-Victorian Prostate Cancer Health Outcomes Research Dataset
por: Ruseckaite, Rasa, et al.
Publicado: (2016)

The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine–oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer
por: Goldstein, D, et al.
Publicado: (2012)

Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial
por: Hoch, Jeffrey S., et al.
Publicado: (2019)

Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo
por: Goodwin, Pamela J, et al.
Publicado: (2021)

The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy – results from the AGITG DOCTOR trial and the cancer evolution biobank
por: Lonie, James M., et al.
Publicado: (2023)

Massive contractions of Myotonic Dystrophy Type 2-associated CCTG tetranucleotide repeats occur via double strand break repair with distinct requirements for helicases
por: Papp, David, et al.
Publicado: (2023)

Psychometric properties of patient-reported outcome measures for dysphagia in head and neck cancer: a systematic review protocol using COSMIN methodology
por: Manduchi, Beatrice, et al.
Publicado: (2022)

Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial
por: Fontana, Elisa, et al.
Publicado: (2020)

Transplant Trial Watch
por: O’Callaghan, John
Publicado: (2022)

Advice about Work-Related Issues to Peers and Employers from Head and Neck Cancer Survivors
por: Dewa, Carolyn S., et al.
Publicado: (2016)

Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti–Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer
por: Topham, James T., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o3pj1taraegn07dagr99qmn1io